NDAORALTABLET1 Generic Approved
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
2
Data completeness
5/8 — Partial
MICARDIS HCT (telmisartan and hydrochlorothiazide) by Boehringer Ingelheim is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 2000.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MICARDIS HCT is a fixed-dose combination oral tablet containing telmisartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) approved in 2000 for hypertension management. It works by blocking angiotensin II receptors to relax blood vessels and reduce fluid retention via diuretic action. The dual mechanism provides additive antihypertensive efficacy for blood pressure control.
$0.947MPart D
LOE ApproachingDeclining
Product is in mature/declining phase with minimal Part D volume, indicating a legacy franchise with limited growth opportunities and likely small team size.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
Started Apr 2006
4,255 enrolled
Hypertension
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
Started Jun 2004
583 enrolled
Hypertension
Career Relevance
Working on MICARDIS HCT offers limited career growth due to its LOE-approaching lifecycle and minimal current job openings (0 linked positions). Roles are predominantly focused on defending market share and managing generic transition rather than launching or growing a franchise.
Worked on MICARDIS HCT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.